Kidney transplantation in the elderly: A decision analysis

Journal of the American Society of Nephrology

Volumn 14, Issue 1, 2003, Pages 187-196

  Jassal, Sarbjit V ^a,b,d   Krahn, Murray D ^a,b   Naglie, Gary ^a,b,c   Zaltzman, Jeffrey S ^a,b   Roscoe, Janet M ^a,b   Cole, Edward H ^a,b   Redelmeier, Donald A ^b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BIOLOGICAL MODEL; CADAVER KIDNEY; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIALYSIS; HEALTH CARE COST; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIFE EXPECTANCY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE;

EID: 12244299827     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000042166.70351.57     Document Type: Article

References (90)

1. Albrechtson D, Leivestad T, Sodal G, Bentdal O, Berg KG, Brekke I, Fauchald P, Flatmark A, Jakobsen A, Lien B, Nordal K, Pfeffer P, Thorsby E, Soreide O: Kidney transplantation in patients older than 70 years of age. Transplant Proc 27: 86-88, 1995
2. Schaubel D, Desmeules M, Mao Y, Jeffery J, Fenton SS: Survival experience among elderly end-stage renal disease patients. Transplantation 60: 1389-1394, 1995
3. Canadian Institute for Health Information. Annual Report 1999, Dialysis and Transplantation, Canadian Organ Replacement Register. 1999. Ottawa, Ontario. Volume 1
4. National Institute of Diabetes and Digestive and Kidney Diseases: U.S: Renal Data Systems, Annual Data Report (on CD). Researchers Guide, Reference Tables and ADR slides Ann Arbor MI, United States Renal Data System Coordinating Center, 2000
5. Wolfe RA, Ashby EL, Milford EL, Ojo AO, Ettenger RE, Agodoa LYC, Held PJ, Port FK: Patient survival for wait-listed dialysis versus cadaveric renal transplant patients in the US. J Am Soc Nephrol 8: 708, 1997
6. Sonnenberg FA, Beck R: Markov models in medical decision making: A practical guide. Med Decis Making 13: 322-338, 1993
7. Rabbat CG, Thorpe KE, Russell JD, Churchill DN: Comparison of mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada. J Am Soc Nephrol 11: 917-922, 2000
8. Beck JR, Kassirer JP, Pauker SG: The convenient approximation of life expectancy (The "DEALE"). I. Validation of the method. Am J Med 73: 883-888, 1982
9. Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP: A convenient approximation of life expectancy (The "DEALE"). II: Use in medical decision making. Am J Med 73: 889-897, 1982
10. David P and Millar, W: Life Tables, Canada and Provinces and Health Reports - Supplement No. 13. 84-537-XPB. 1995. Statistics Canada
11. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, Held PJ, Port FK: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Eng J Med 341: 1725-1730, 1999
12. The Tricontinental mycophenylate mofetil renal transplantation study group: A blinded, randomized clinical trial of mycophenylate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61: 1029-1037, 1996
13. Sullivan SD, Garrison LP, Best JH, and members of the US Renal Transplant Mycophenolate Mofetil study group: The cost effectiveness of mycophenolate mofetil in the first year after primary cadaveric transplant. J Am. Soc Nephrol 8: 1592-1598, 1997
14. Cole EH, Farewell VT, Aprile M, Cattran DC, Pei YP, Fenton SS, Zaltzman J, Cardella CJ: Renal transplantation in older patients: The University of Toronto experience. Ger Nephrol Urol 5: 85-92, 1995
15. Riera L, Seron D, Castelao AM, Grino JM, Franco E, Bover J, Vigues L, Alsina J, Serrallach N: Renal transplantation in cyclosporin-treated patients over age 50. Transplant Proc 24: 122-123, 1992
16. Morales JM, Munoz MA, Campo C, Andres A, Araque A, Alamo C, Praga M, Ortuno T, Hernandez E, Rodicio JL: Renal transplantation in older patients with double therapy with optional change to cyclosporin monotherapy: Long term results. Transplant Proc 26: 2511-2512, 1994
17. Andreu J, de la Torre M, Oppenheimer F, Campistol, JM, Ricart MJ, Vilardell J, Talbot R, Carretero P: Renal transplantation in elderly recipients. Transplant Proc 24: 120-121, 1992
18. Morris GE, Jamieson NV, Small J, Evans DB, Calne SR: Cadaveric renal transplantation in elderly recipients: Is it worthwhile ? Nephrol Dial Transplant 6: 887-892, 1991
19. MacDonell RC, Van Buren DH, Richie RE, Johnson HK, Nylander WA, Hledlerman JH, Ynares CM, Trusler LA, Green WF, Crowe DA: Kidney transplantation at extremes of age: CsA eliminates the increased risk in recipients /= 55 years. Transplant Proc 26: 2518-2521, 1994
20. Spanish Monotherapy Study Group: Cyclosporine monotherapy versus OKT3 and cyclosporin versus prednisone and cyclosporine as induction therapy in older renal transplant patients: A multicenter randomized study. Transplant Proc 26: 2522-2524, 1994
21. Lundgren G, Persson NH, Albrechtson D, Brynger H, Flatmark A, Frodin L, Groth CG, Lindholm A, Weibull H: Recipient agean important factor for the outcome of cadaver renal transplantation in patients treated with cyclosporine. Transplant Proc 21: 1653-1654, 1989
22. Kock B, Kuhlback B, Ahonen J: Kidney transplantation in patients over 60 years of age. Scand J Urol Nephrol 54: 203-205, 1980
23. Meier-Kreische HU, Ojo A, Hanson J, Cibrik D, Lake K, Agodoa LY, Leichtman A, Kaplan B: Increased immunosuppressive vulnerability in elderly renal transplant recipients. Transplantation 69: 885-889, 2000
24. Meier-Kreische HU, Friedman G, Jacobs M, Mulgaonkar S, Vaghela M, Kaplan B: Infectious complications in geriatric renal transplant patients: Comparison of two immunosuppressive protocols. Transplantation 68: 1496-1502, 1999
25. Mayer AD, Dmitrewski J, Squifflet J, Besse T, Grabensee B, Klein B, Eigler FW, Heeman U, Pichlmayr R, Behrend M, Vanrenterghem Y, Donck J, van Hooff J, Christiaans M, Morales JM, Andres A, Johnson RWG, Short C, Buchholz B, Rehmert N, Land W, Schleibner S, Forsythe JLR, Talbot D, Neumayer H, Hauser I, Ericzon B, Brattrstrom C, Claesson K, Muhlbacher F, Pohanka E: Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporin in the prevention of renal allograft rejection. Transplantation 64: 436-443, 1997
26. Papadakis J, Brown CB, Cameron JS, Adu D, Bewick M, Donaghey R, Ogg CS, Rudge C, Williams DG, Taube D: High versus "low" dose corticosteroids in recipients of cadaveric kidneys: Prospective controlled trial. BMJ (Clin Research Ed). 286: 1097- 1100, 1983
27. Stratta RJ, Taylor RJ, Sindhi R, Sudan D, Jerius JT, Gill IS: Analysis of early readmissions after combined pancreas-kidney transplantation. Am J Kidney Dis 28: 867-877, 1996
28. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group. N Eng J Med 313: 337-342, 1985
29. Midtvedt K, Tafjord AB, Hartmann A, Eide TC; Holdaas H; Nordal KP; Draganov B; Sodal G.; Leivestad T, Fauchald P: Half dose of OKT3 is efficient in treatment of steroid-resistant renal allograft rejection. Transplantation 62: 38-42, 1996
30. Woodle ES, Thistlethwaite JR, Gordon JH, Laskow D, Deierhoi MH, Burdick J, Pirsch JD, Sollinger H, Vincenti F, Burrows L, Schwartz B, Danovitch GM, Wilkinson AH, Shaffer D, Simpson MA, Freeman RB, Rohrer RJ, Mendez R, Aswad S, Munn SR, Wiesner RH, Delmonico FL, Neylan J, Whelchel J: A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. Transplantation 62: 594-599, 1996
31. Jordan M, Shapiro R, Vivas CA, Scantlebury VP; Rhandhawa P; Carrieri G; McCauley J; Demetris AJ; Tzakis A, Fung J, Simmons RL, Hakala TR, Starzl TE: FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 57: 860-865, 1994
32. Siegel RR, Aquino HC, Luke RG, Schmidt R: Minimising the risks of treating acute allograft rejection. Proc Eur Dial Trans Assoc 11: 351-356, 1975
33. Matas AJ, Tellis VA, Quinn T, Glichlick D, Soberman R, Weiss R, Karwa G, Veith FJ: ALG treatment of steroid-resistant rejection in patients receiving cyclosporine. Transplantation 41: 579-583, 1986
34. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D: Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Eng. J Med 342: 605-612, 2000
35. Fryer JP, Granger DK, Leventhal JR, Gillingham K, Najarian JS, Matas AJ: Steroid-related complications in the cyclosporine era. Clinical Transplant 8: 224-229, 1994
36. Tornatore KM, Biocevich DM, Reed KA, Tousley K, Gray V, Singh JP, Murray BM, Venuto RC: Post-transplant diabetes mellitus and methylprednisolone pharmacokinetics in African-American and Caucasian renal transplant recipients. Clinical Transplant 9: 289-296, 1995
37. Saxena S, Dash SC, Guleria S, Mittal R, Agarwal SK, Tiwari SC, Mehta SN: Post transplant diabetes mellitus in live related renal allograft recipients: A single centre experience. J Assoc Physicians India 44: 472-479, 1996
38. Filler G, Amendt P, von Bredow MA, Ehrich JH: Transient diabetes mellitus and peripheral insulin resistance following Tacrolimus intoxication in a child after renal transplantation. Nephrol Dial Transplant 12: 334-336, 1997
39. Kim YS, Kim MS, Kim SI, Lim SK, Lee HY, Han DS, Park K: Post-transplantation diabetes is better controlled after conversion from prednisone to deflazacort: A prospective trial in renal transplants. Transpl Int 10: 197-201, 1997
40. Isoniemi HM, Ahonen J, Tikkanen MJ, van Willebrand EO, Krogerus L, Eklund BH, Hockerstedt KV, Salmela KE, Hayry PJ: Long-term consequences of different immunosuppressive regimens for renal allografts. Transplantation 55: 494-499, 1993
41. Vesco L, Busson M, Lang P: Characteristics of postrenal transplant diabetes mellitus. Transplant Proc 27: 2465-2466, 1995
42. Hjelmesaeth J, Hartmann A, Kofstad J, Stenstrom J, Leivestad T, Egeland T, Fauchald P: Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 64: 979-983, 1997
43. Sakhuja V, Sharma UK, Jha V, Minz M, Chugh KS: High incidence of posttransplant diabetes mellitus in renal transplant recipients on triple-drug immunosuppression. Transplant Proc 27: 2728-2730, 1995
44. Lee HC, Nam MS, Nam SY, Cha BS, Lee JH, Song YD, Lee EJ, Lim SK, Kim KR, Kim YS, Park K, Huh KB: Posttransplant diabetes mellitus after renal transplantation in Korea. Transplant Proc 28: 1159-1160, 1996
45. Tanabe K, Koga S, Takahashi K, Sonda K, Tokumoto T, Babazono T, Yagisawa T, Toma H, Kawai T, Fuchinoue S, Teraoka S, Ota K: Diabetes mellitus after renal transplantation under FK506 (tacrolimus) as primary immunosuppression. Transplant Proc 28: 1304-1305, 1996
46. Lanerolle RD, de Abrew K, Fernando DJ, Sheriff MH: Post-renal transplant diabetes in Sri Lanka. Transplant Proc 28: 1945- 1947, 1996
47. Churchill DN, Torrance GW, Taylor DW, Barnes CC, Ludwin D, Shimizu A, Smith EKM: Measurement of quality of life in end-stage renal disease: The time trade off approach. Clin Invest Med 10: 14-20, 1987
48. Douzdjian V, Bunke CM, Ferrara D, Silvestri G: A utility-based decision analysis model for treatment of type I diabetics with ESRD: Dialysis versus kidney transplant versus kidney-pancreas transplant. J Am Soc Nephrol 8: 680A, 1997
49. Laupacis A, Wong C, Churchill DN, The Canadian Erythropoietin Study Group: The use of generic and specific quality of life measures in haemodialysis patients treated with erythropoeitin. Control Clin Trials 12: 168S-179S, 1991
50. Laupacis A, Muirhead N, Keown P, Wong C: A disease-specific questionnaire for assessing quality of life in patients on hemodialysis. Nephron 60: 302-306, 1992
51. Laupacis A, Keown P, Pus N, Ferguson B, Wong C, Muirhead N: A study of the quality of life and cost-utility of renal transplantation. Kidney Int 50: 235-242, 1996
52. Russell JD, Beecroft ML, Ludwin D, Churchill DN: The quality of life in renal transplantation - A prospective study. Transplantation 54: 656-660, 1992
53. Churchill DN, Wallace JE, Ludwin D, Beecroft ML, Taylor DW: A comparison of evaluative indices of quality of life and cognitive function in hemodialysis patients. Control Clin Trials 12: 159S-167S, 1991
54. Goeree R, Manalich J, Grootendorst P, Beecroft ML, Churchill DN: Cost analysis of dialysis treatments for end-stage renal disease (ESRD). Clinical & Investigative Medicine - Medecine Clinique et Experimentale 18: 455-464, 1995
55. Khan IH, MacLeod AM: Towards cost-effective dialysis therapy in Europe: The need for a multidisciplinary approach. Nephrol Dial Transplant 12: 2483-2485, 1998
56. Bruns F, Seddon P, Saul M, Zeidel M: The cost of caring for end-stage kidney disease patients: an analysis based on hospital financial transaction records. J Am Soc Nephrol 9: 884-890, 1998
57. Garella S: The costs of dialysis in the USA. Nephrol Dial Transplant 12 Suppl 1: 10-21, 1997
58. Cogny-Van Weydevelt F, Ngohou C, Pontefract R, Bacquaert-Dufour K, Riberi P: Hemodialysis and transplantation cost-effectiveness analysis. Transplant Proc 28: 2838-2838, 1996
59. Madrigal G: Cost estimate of kidney transplants in Costa Rica: Comparison to chronic dialysis. Transplant Proc 26: 121-121, 1994
60. Shield CF3, Jacobs RJ, Wyant S, Das A: A cost-effectiveness analysis of OKT3 induction therapy in cadaveric kidney transplantation. Am J Kidney Dis 27: 855-864, 1996
61. Kiberd BA: Should hepatitis C-infected kidneys be transplanted in the United States? Transplantation 57: 1068-1072, 1994
62. Eggers PW: Comparison of treatment costs between dialysis and transplantation. Semin Nephrol 12: 284-289, 1992
63. Lenisa L, Castoldi R, Socci C, Motta F, Ferrari G, Spotti D, Caldara R, Secchi A, Pozza G, Di Carlo V: Cost-effective treatment for diabetic end-stage renal disease: Dialysis, kidney, or kidney-pancreas transplantation? Transplant Proc 27: 3108-3113, 1995
64. Prichard SS: The costs of dialysis in Canada. Nephrol Dial Transplant 12 Suppl 1: 22-24, 1997
65. Sullivan SD, Garrison LP, Best JH, and members of the US Renal Transplant Mycophenylate Mofetil study group: The cost effectiveness of mycophenylate mofetil in the first year after primary cadaveric transplant. J Am Soc Nephrol 8: 15981997
66. Neylan JF, Sullivan EM, Prendergast MM, Steinwald AB, Goss TF, FK506 Kidney Transplant Study Group: An Economic Assessment of Post-Transplant Hospitalizations Among Kidney Transplant Patients Receiving Tacrolimus Versus Cyclosporin Immunosuppressive Therapy. The International Congress of Immunosuppression, Orlando 1998
67. Morris-Stiff G, Richards T, Baboolal K, Balaji V, Ostrowski K, Moore R, Darby C, Lord R, and Jurewicz, A: Pharmaco-Economic Study of Tacrolimus and Neoral in Cadaveric Renal Transplantation. The British Transplantation Society, Dublin 1998
68. Oliveira, D: Economic analysis of Prograf (tacrolimus) and cyclosporin in the prevention of kidney allograft rejection. New Horizons in Kidney Transplantation 1: 12-15, 1997
69. Internet address: http:/www/oanda.com/cgi_bin/ncc.
70. Bureau of Labor Statistics. 1998
71. Krahn M, Gafni A: Discounting in the economic evaluation of health care interventions. Med Care 31: 403-418, 1993
72. Evans RW, Kitzmann DJ: An economic analysis of kidney transplantation. Surg Clin North Am 78: 149-174, 1998
73. Karlberg I, Nyberg G: Cost-effectiveness studies of renal transplantation. Int J Technol Assess Health Care 11: 611-622, 1995
74. Mallick NP: The costs of renal services in Britain. Nephrol Dial Transplant 12 Suppl 1:25-28, 1997
75. Department of Health and Human Services, Health Care Financing Administration Bureau of Data Management and Strategy Office of Research and Demonstrations. Health Care Financing. End Stage Renal Disease. 1997. Baltimore, MD
76. Levine DZ: Would you deny this patient dialysis? Am J Kidney Dis 31: 131-132, 1998
77. Naimark D, Naglie G, Detsky AS: The meaning of life expectancy: What is a clinically significant gain? J Gen Intern Med 9: 702-707, 1994
78. O'Brien BJ, Anderson DR, Goeree R: Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. Can Med Assoc J 150: 1083-1090, 1994
79. Weinstein MC, Stason WB: Cost-effectiveness of interventions to prevent or treat coronary heart disease. Ann Rev Public Health 6: 41-63, 1985
80. Azimi NA, Welch HG: The effectiveness of cost-effectiveness analysis in containing costs. J Gen Intern Med 13: 664-669, 1998
81. Ismail N, Hakim R, Helderman JH: Renal replacement therapies in the elderly: Part II renal transplantation. Am J Kidney Dis 23: 1-15, 1994
82. Jassal SV, Opelz G, Cole E: Transplantation in the elderly: A review. Ger Nephrol Urol 7: 157-165, 1997
83. Manninen DL, Evans RW: The costs and outcomes of kidney transplantation according to initial immunosuppressive drug protocol. Clin Transplant 269: 275, 1987
84. National Kidney Foundation-Dialysis Outcomes Quality Initiative Guidelines. 1997. Washington, National Kidney Foundation
85. Velez RL, Brinker KR, Vergne-Marinin PJ, Nesser DA, Long DL, Trevino G, Dickerman RM, Helfsick GB: Renal transplantation with cyclosporine in the elderly population. Transplant Proc 23: 1749-1752, 1991
86. Parfrey PS, Hutchinson TA, Harvey C, Guttman RD: Transplantation versus dialysis in diabetic patients with renal failure. Am J Kidney Dis 5: 112-116, 1985
87. Rao KV: The influence of preexisting vascular disease on the outcome of renal transplantation in diabetic patients. Nephron 48: 74-75, 1988
88. Basadonna G, Matas AJ, Gillingham K, Sutherland DE, Payne WD, Dunn DL, Gores PF, Gruessner RW, Arrazola L, Najarian JS: Kidney transplantation in patients with type I diabetes: 26-Year experience at the University of Minnesota. Clin Transplant 227: 235, 1992
89. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ: Cardiovascular disease after renal transplantation. J Am Soc Nephrol 7: 158-165, 1996
90. Peters TG, Jones KW, Walker GW, Charlton RK, Antonucci LE, Repper SM, Hunter RDS: Living-unrelated kidney donation: A single center experience. Clinical Transplant 13: 108-112, 1999